Literature DB >> 6782605

Alterations in cerebrospinal fluid dopamine metabolites following physostigmine infusion.

K L Davis, K F Faull, L E Hollister, J D Barchas, P A Berger.   

Abstract

The effect of IV physostigmine administration on the cerebrospinal fluid (CSF) levels of homovanillic acid (HVA) and dihydroxyphenylacetic acid (DOPAC) in normal subjects was determined. After an adjustment for differing CSF concentrations of probenecid, physostigmine was found to elevate CSF HVA and DOPAC concentrations. The authors discuss these changes in CSF HVA and DOPAC and their possible relationship to the ability of physostigmine to decrease the symptoms of some patients with tardive dyskinesia.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 6782605     DOI： 10.1007/BF00431649

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN： 0033-3158            Impact factor:   4.530


  60 in total

1.  MODIFICATION BY DRUGS OF THE METABOLISM OF 3,4-DIHYDROXYPHENYLETHYLAMINE, NORADRENALINE AND 5-HYDROXYTRYPTAMINE IN THE BRAIN.

Authors:  R LAVERTY; D F SHARMAN
Journal:  Br J Pharmacol Chemother       Date:  1965-06

2.  Choline in tardive dyskinesia and Huntington's disease.

Authors:  K L Davis; L E Hollister; J D Barchas; P A Berger
Journal:  Life Sci       Date:  1976-11-15       Impact factor: 5.037

3.  Physostigmine in choreiform movement disorders.

Authors:  D Tarsy; N Leopold; D S Sax
Journal:  Neurology       Date:  1974-01       Impact factor: 9.910

4.  Uptake and release of -aminobutyric acid (GABA) in slices of substantia nigra of rat.

Authors:  Y Okada; R Hassler
Journal:  Brain Res       Date:  1973-01-15       Impact factor: 3.252

5.  Proceedings: Pharmacological studies on single neurones in the substantia nigra of the rat.

Authors:  A R Crossman; R J Walker; G N Woodruff
Journal:  Br J Pharmacol       Date:  1974-05       Impact factor: 8.739

6.  Central dopaminergic neurons: effects of alterations in impulse flow on the accumulation of dihydroxyphenylacetic acid.

Authors:  R H Roth; L C Murrin; J R Walters
Journal:  Eur J Pharmacol       Date:  1976-03       Impact factor: 4.432

7.  Application of seady-state kinetics to studies of the transfer of 5-hydroxyindoleacetic acid from brain to plasma.

Authors:  N H Neef; T N Tozer; B B Brodie
Journal:  J Pharmacol Exp Ther       Date:  1967-11       Impact factor: 4.030

8.  Effect of cholinergic and anticholinergic agents on tardive dyskinesia.

Authors:  H L Klawans; R Rubovits
Journal:  J Neurol Neurosurg Psychiatry       Date:  1974-08       Impact factor: 10.154

9.  Release to the cerebral ventricles of substances with possible transmitter function in the caudate nucleus.

Authors:  P J Portig; M Vogt
Journal:  J Physiol       Date:  1969-10       Impact factor: 5.182

Review 10.  Emerging treatments: replacement therapy with choline or lecithin in neurological diseases.

Authors:  A Barbeau
Journal:  Can J Neurol Sci       Date:  1978-02       Impact factor: 2.104
View more
  4 in total

Review 1.  Acetylcholinesterase inhibitors for schizophrenia.

Authors:  Jasvinder Singh; Kamalpreet Kour; Mahesh B Jayaram
Journal:  Cochrane Database Syst Rev       Date:  2012-01-18

2.  Changes in dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC) levels in human cerebrospinal fluid after L-dopa and deprenyl administration.

Authors:  K Baraczka; M I Fekete; B Kanyicska
Journal:  J Neural Transm       Date:  1983       Impact factor: 3.575

3.  Increased CSF HVA response to arecoline challenge in Alzheimer's disease.

Authors:  N Pomara; M Stanley; P A LeWitt; M Galloway; R Singh; D Deptula
Journal:  J Neural Transm Gen Sect       Date:  1992

4.  On the significance of monoamines and their metabolites in the cerebrospinal fluid of the sheep.

Authors:  M Ruckebusch; J F Sutra
Journal:  J Physiol       Date:  1984-03       Impact factor: 5.182
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.